The goal of OTR3® is to continue exploring the potential of the RGTA® Technology, developing new indications and innovative healthcare products. Our expansion relies on extensive cutting-edge research and development that will allow us to bring to patients innovative therapeutic solutions that really make a difference.

OTR3® focuses on extending its portfolio to a wider range of new products, each based on RGTA® molecules tailored for the treatment of specific diseases.

OTR3® doesn’t sell directly its products to the patient. The commercialisation of our products is licensed out to a network of pharmaceutical companies throughout the world.